Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.

Gregson SJ, Masterson LA, Wei B, Pillow TH, Spencer SD, Kang GD, Yu SF, Raab H, Lau J, Li G, Lewis Phillips GD, Gunzner-Toste J, Safina BS, Ohri R, Darwish M, Kozak KR, Dela Cruz-Chuh J, Polson A, Flygare JA, Howard PW.

J Med Chem. 2017 Dec 14;60(23):9490-9507. doi: 10.1021/acs.jmedchem.7b00736. Epub 2017 Nov 16.

PMID:
29112410
2.

Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.

Backman JD, O'Connell JR, Tanner K, Peer CJ, Figg WD, Spencer SD, Mitchell BD, Shuldiner AR, Yerges-Armstrong LM, Horenstein RB, Lewis JP.

Pharmacogenet Genomics. 2017 Apr;27(4):159-163. doi: 10.1097/FPC.0000000000000272.

3.

Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine.

Andey T, Patel A, Marepally S, Chougule M, Spencer SD, Rishi AK, Singh M.

PLoS One. 2016 Jan 12;11(1):e0146804. doi: 10.1371/journal.pone.0146804. eCollection 2016.

4.

Contribution of Aggregate States and Energetic Disorder to a Squaraine System Targeted for Organic Photovoltaic Devices.

Zheng C, Penmetcha AR, Cona B, Spencer SD, Zhu B, Heaphy P, Cody JA, Collison CJ.

Langmuir. 2015 Jul 21;31(28):7717-26. doi: 10.1021/acs.langmuir.5b01045. Epub 2015 Jul 13.

PMID:
26132332
5.

An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.

Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, Dennis MS, Spencer SD.

Mol Cancer Ther. 2014 Nov;13(11):2630-40. doi: 10.1158/1535-7163.MCT-14-0487-T. Epub 2014 Sep 23.

6.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
7.

A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12. doi: 10.1016/j.jchromb.2013.10.023. Epub 2013 Oct 22.

8.

The CYP2C19*17 variant is not independently associated with clopidogrel response.

Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, Shuldiner AR.

J Thromb Haemost. 2013 Sep;11(9):1640-6. doi: 10.1111/jth.12342.

9.

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.

BJU Int. 2013 Jun;111(8):1269-80. doi: 10.1111/j.1464-410X.2012.11667.x. Epub 2013 Feb 18.

10.

A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.

Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:142-6. doi: 10.1016/j.jchromb.2013.01.003. Epub 2013 Jan 9.

11.

Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.

BMJ Open. 2013 Jan 3;3(1). pii: e002030. doi: 10.1136/bmjopen-2012-002030.

12.

Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.

Blood. 2013 Jan 17;121(3):476-84. doi: 10.1182/blood-2012-08-450585. Epub 2012 Dec 3.

13.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.

Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR.

Pharmacogenet Genomics. 2013 Jan;23(1):1-8. doi: 10.1097/FPC.0b013e32835aa8a2.

14.

Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.

Oncologist. 2012;17(3):312-20. doi: 10.1634/theoncologist.2011-0315. Epub 2012 Mar 1.

15.

Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM).

Patel AR, Spencer SD, Chougule MB, Safe S, Singh M.

Eur J Pharm Sci. 2012 May 12;46(1-2):8-16. doi: 10.1016/j.ejps.2012.01.012. Epub 2012 Feb 8.

16.

Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Chen X, Peer CJ, Alfaro R, Tian T, Spencer SD, Figg WD.

J Pharm Biomed Anal. 2012 Mar 25;62:140-8. doi: 10.1016/j.jpba.2012.01.008. Epub 2012 Jan 16.

17.

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR.

Nat Biotechnol. 2012 Jan 22;30(2):184-9. doi: 10.1038/nbt.2108.

PMID:
22267010
18.
19.

A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.

Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jan 1;880(1):132-9. doi: 10.1016/j.jchromb.2011.11.029. Epub 2011 Nov 26.

20.

Phylogenetic analysis of the nucleoprotein gene of measles viruses prevalent in Nantong, Jiangsu Province, China, during 2010.

Li H, Spencer SD, Lian L, Zhang Z, Lu P.

Epidemiol Infect. 2012 Sep;140(9):1607-11. doi: 10.1017/S0950268811002433. Epub 2011 Nov 25.

PMID:
22117136
21.

Hepatitis B virus with pre-S2 deletion is more prevalent in hepatocellular carcinoma than in chronic active hepatitis and asymptomatic carriers.

Li H, Qiang F, Yang Z, Spencer SD, Cui X, Wu X, Chen X.

Acta Virol. 2011;55(2):183-5. No abstract available.

PMID:
21692570
22.

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G.

Clin Cancer Res. 2011 Aug 1;17(15):5123-31. doi: 10.1158/1078-0432.CCR-11-0682. Epub 2011 Jun 14.

23.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

24.
25.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

26.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

27.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
28.
29.

Protonation effect on drug affinity.

Raffa RB, Stagliano GW, Spencer SD.

Eur J Pharmacol. 2004 Jan 12;483(2-3):323-4.

PMID:
14729124
30.

Toward RNase inhibitors: thermodynamics of 2'-CMP/RNase-A binding in multi-ion buffer.

Raffa RB, Spencer SD, Schulingkamp RJ.

Biochem Pharmacol. 2002 Jun 1;63(11):1937-9.

PMID:
12093469
31.

Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase A.

Spencer SD, Abdul O, Schulingkamp RJ, Raffa RB.

J Pharmacol Exp Ther. 2002 Jun;301(3):925-9.

32.

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H.

Cancer Res. 2002 May 1;62(9):2546-53.

35.

The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor.

Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, Sordat B, Gibbs VC, Aguet M.

J Exp Med. 1998 Feb 16;187(4):571-8.

36.

Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits.

Chen KS, Nishimura MC, Armanini MP, Crowley C, Spencer SD, Phillips HS.

J Neurosci. 1997 Oct 1;17(19):7288-96.

37.

Human trks: molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins.

Shelton DL, Sutherland J, Gripp J, Camerato T, Armanini MP, Phillips HS, Carroll K, Spencer SD, Levinson AD.

J Neurosci. 1995 Jan;15(1 Pt 2):477-91.

38.

Suppression of mammalian 5' splice-site defects by U1 small nuclear RNAs from a distance.

Cohen JB, Snow JE, Spencer SD, Levinson AD.

Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10470-4.

39.

Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells.

Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W.

Blood. 1994 Oct 15;84(8):2422-30.

40.

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, et al.

Nature. 1994 Jun 16;369(6481):533-8.

PMID:
8202154
41.

Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons.

Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, McMahon SB, Shelton DL, Levinson AD, et al.

Cell. 1994 Mar 25;76(6):1001-11.

PMID:
8137419

Supplemental Content

Loading ...
Support Center